Chapter 40 : Vaccines and Antibody Therapies from to Melanoma

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Vaccines and Antibody Therapies from to Melanoma, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap40-1.gif /docserver/preview/fulltext/10.1128/9781555816858/9781555815011_Chap40-2.gif


This chapter talks about recent developments in the vaccine field and the publication of two recent comprehensive reviews that include additional information on the problem of vaccination against . is an encapsulated pathogen, and polysaccharide-based vaccines have an excellent track record in eliciting protective immunity against bacteria with polysaccharide capsules. Human MAbs produced from immortalized B cells from glucuronoxylomannan (GXM)-TT-vaccinated individuals were protective in mice, and serum antibodies from vaccinated individuals enhanced the antifungal activity of phagocytes against . Peptide mimotopes of GXM selected by mouse and human MAbs have been reported. An advantage of peptide mimotopes is that they can be made easily and reproducibly and thus provide an attractive option for generating vaccines. Site-directed mutagenesis of the binding contacts of a protective MAb revealed that different amino acids were involved in binding to polysaccharide and mimotope epitopes, raising the possibility that different types of antibodies are elicited by carbohydrate and peptide antigens. Cryptococcal infection elicits strong and rapid antibody responses to fungal proteins, such as heat shock proteins (HSPs), but currently there is no evidence that these antibody responses contribute to host protection. In the late 1990s murine MAbs were made to melanin with the goal of using these reagents for the study of melanization in vivo and in vitro. Subsequently, it was hypothesized that if these MAbs bound to human melanin, they could be used to deliver tumoricidal radiation to melanoma cells.

Citation: Casadevall A, Dadachova E, Pirofski L. 2011. Vaccines and Antibody Therapies from to Melanoma, p 537-546. In Heitman J, Kozel T, Kwon-Chung K, Perfect J, Casadevall A (ed), . ASM Press, Washington, DC. doi: 10.1128/9781555816858.ch40
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Abadi, J., and, L. Pirofski. 1999. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection. J. Infect. Dis. 180: 915919.
2. Alpe, M.,, P. Svahnberg, and, S. Oscarson. 2003. Synthesis of Cryptococcus neoformans capsular polysaccharide structures. Part IV. Construction of thioglycoside donor blocks and their assembly. J. Carbohydr. Chem. 22: 565577.
3. Alpe, M.,, P. Svahnberg, and, S. Oscarson. 2004. Synthesis of Cryptococcus neoformans capsular polysaccharide structures. Part V. Construction of uronic acid-containing thioglycoside donor. J. Carbohydr. Chem. 23: 411424.
4. Baronetti,, J. L.,, L. S. Chiapello,, M. P. Aoki,, S. Gea, and, D. T. Masih. 2006. Heat killed cells of Cryptococcus neoformans var. grubii induces protective immunity in rats: immunological and histopathological parameters. Med. Mycol. 44: 493504.
5. Beenhouwer,, D. O.,, R. J. May,, P. Valadon, and, M. D. Scharff. 2002. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. J. Immunol. 169: 69926999.
6. Beenhouwer, D. O.,, P. Valadon,, R. May, and, M. D. Scharff. 2000. Peptide mimicry of the polysaccharide capsule of Cryptococcus neoformans, p. 143–160. In M. W. Cunningham and, R. S. Fujinami (ed.), Molecular Mimicry, Microbes and Autoimmunity. ASM Press, Washington, DC.
7. Beenhouwer,, D. O.,, E. M. Yoo,, C. W. Lai,, M. A. Rocha, and, S. L. Morrison. 2007. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect. Immun. 75: 14241435.
8. Bennett, J. E., and, H. F. Hasenclever. 1965. Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection. J. Immunol. 94: 916920.
9. Biondo,, C.,, G. Mancuso,, A. Midiri,, M. Bombaci,, L. Messina,, C. Beninati, and G. Teti. 2006. Identification of major proteins secreted by Cryptococcus neoformans. FEMS Yeast Res. 6: 645651.
10. Bonham, S.,, D. B. Meya,, P. R. Bohjanen, and, D. R. Boulware. 2008. Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark. Med. 2: 349361.
11. Bryan,, R. A.,, Z. Jiang,, X. Huang,, A. Morgenstern,, F. Bruchertseifer,, R. Sellers,, A. Casadevall, and E. Dadachova. 2009. Radioimmunotherapy is effective against high-inoculum Cryptococcus neoformans infection in mice and does not select for radiation-resistant cryptococcal cells. Antimicrob. Agents Chemother. 53: 16791682.
12. Buchanan, K. L., and, J. W. Murphy. 1993. Characterization of cellular infiltrates and cytokine production during the expression of the anticryptococcal delayed-type hypersensitivity response. Infect. Immun. 61: 28542865.
13. Casadevall,, A.,, W. Cleare,, M. Feldmesser,, A. Glatman-Freedman,, D. L. Goldman,, T. R. Kozel,, N. Lendvai,, J. Mukherjee,, L. Pirofski,, J. Rivera,, A. L. Rosas,, M. D. Scharff,, P. Valadon,, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptocococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemotherap. 42: 14371446.
14. Casadevall,, A.,, J. Mukherjee,, S. J. N. Devi,, R. Schneerson,, J. B. Robbins, and, M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65: 10861093.
15. Casadevall, A., and, L. Pirofski. 2003. Exploiting the redundancy of the immune system: vaccines can mediate protection by eliciting ‘unnatural’ immunity. J. Exp. Med. 197: 14011404.
16. Casadevall, A., and, L. A. Pirofski. 2005. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med. Mycol. 43: 667680.
17. Chen,, L.-C.,, D. L. Goldman,, T. L. Doering,, L. Pirofski, and A. Casadevall. 1999. Antibody response to Cryptococcus neoformans proteins in rodents and humans. Infect. Immun. 67: 22182224.
18. Cutler, J. E.,, G. S. Deepe, Jr., and, B. S. Klein. 2007. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5: 1328.
19. Dadachova,, E.,, R. A. Bryan,, C. Apostolidis,, A. Morgenstern,, T. Zhang,, T. Moadel,, M. Torres,, X. Huang,, E. Revskaya, and A. Casadevall. 2006. Interaction of radiolabeled antibodies with fungal cells and components of the immune system in vitro and during radioimmunotherapy for experimental fungal infection. J. Infect. Dis. 193: 14271436.
20. Dadachova,, E.,, R. A. Bryan,, A. Frenkel,, T. Zhang,, C. Apostolidis,, J. S. Nosanchuk,, J. D. Nosanchuk, and A. Casadevall. 2004. Evaluation of acute hematologic and long-term pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans infection in murine models. Antimicrob. Agents Chemother. 48: 10041006.
21. Dadachova,, E.,, T. Burns,, R. A. Bryan,, C. Apostolidis,, M. W. Brechbiel,, J. D. Nosanchuk,, A. Casadevall, and L. Pirofski. 2004. Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob. Agents Chemother. 48: 16241629.
22. Dadachova, E., and, A. Casadevall. 2005. Melanin as a potential target for radionuclide therapy of metastatic melanoma. Future Oncol. 1: 541549.
23. Dadachova, E., and, A. Casadevall. 2006. Renaissance of targeting molecules for melanoma. Cancer Biother. Radiopharm. 21: 545552.
24. Dadachova, E.,, A. Nakouzi,, R. A. Bryan, and, A. Casadevall. 2003. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl. Acad. Sci. USA 100: 1094210947.
25. Dadachova,, E.,, J. D. Nosanchuk,, S. Li,, A. D. Schweitzer,, A. Frenkel,, J. S. Nosanchuk, and A. Casadevall. 2004. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc. Natl. Acad. Sci. USA 101: 1486514870.
26. Dadachova,, E.,, M. C. Patel,, S. Toussi,, C. Apostolidis,, A. Morgenstern,, M. W. Brechbiel,, M. K. Gorny,, S. Zolla-Pazner,, A. Casadevall, and H. Goldstein. 2006. Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS. Med. 3: E427.
27. Datta, K.,, A. Lees, and, L. A. Pirofski. 2008. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxy-lomannan. Clin. Vaccine Immunol. 15: 11761187.
28. Datta, K., and, L. A. Pirofski. 2006. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res. 6: 525536.
29. Deepe, G. S., Jr. 2004. Preventative and therapeutic vaccines for fungal infections: from concept to implementation. Expert. Rev. Vaccines 3: 701709.
30. De Jesus,, M.,, A. M. Nicola,, S. Frases,, I. R. Lee,, S. Mieses, and A. Casadevall. 2009. Galactoxylomannanmediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage. J. Immunol. 183: 38853894.
31. Devi, S. J. N. 1996. Preclinical efficacy of a glucuronoxy-lomannantetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14: 841842.
32. Devi,, S. J. N.,, R. Schneerson,, W. Egan,, T. J. Ulrich,, D. Bryla,, J. B. Robbins, and, J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59: 37003707.
33. Dromer, F., and, J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti- Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163: 11141120.
34. Dromer, F.,, J. Charreire,, A. Contrepois,, C. Carbon, and, P. Yeni. 1987. Protection of mice against experimental cryptococcosis by anti- Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55: 749752.
35. Dromer,, F.,, J. Salamero,, A. Contrepois,, C. Carbon,, and P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55: 742748.
36. Eigenheer,, R. A.,, L. Y. Jin,, E. Blumwald,, B. S. Phinney, and A. Gelli. 2007. Extracellular glycosylphosphatidylinositol-anchored mannoproteins and proteases of Cryptococcus neoformans. FEMS Yeast Res. 7: 499510.
37. Feldmesser, M.,, Y. Kress,, P. Novikoff, and, A. Casadevall. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68: 42254237.
38. Feldmesser, M.,, J. Mukherjee, and, A. Casadevall. 1996. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob. Chemother. 37: 617622.
39. Fleuridor, R.,, A. Lees, and, L. Pirofski. 2001. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166: 10871096.
40. Fleuridor, R.,, R. H. Lyles, and, L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180: 15261535.
41. Fleuridor, R.,, Z. Zhong, and, L. Pirofski. 1998. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J. Infect. Dis. 178: 12131216.
42. Frases,, S.,, L. Nimrichter,, N. B. Viana,, A. Nakouzi, and A. Casadevall. 2008. Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences. Eukaryot. Cell 7: 319327.
43. Garegg, P. J.,, L. Olsson, and, S. Oscarson. 1996. Synthesis of oligosaccharides corresponding to structures found in capsular polysaccharides of Cryptococcus neoformans—II. Bioorg. Med. Chem. 4: 18671871.
44. Goldman, D.,, S. C. Lee, and, A. Casadevall. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun. 62: 47554761.
45. Goldman, D. L.,, A. Casadevall, and, L. S. Zuckier. 1997. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy. J. Med. Vet. Mycol. 35: 271278.
46. Goldman,, D. L.,, J. Davis,, F. Bommartio,, X. Shao, and A. Casadevall. 2006. Enhanced allergic inflammation and airway responsiveness in rats with chronic Cryptococcus neoformans infection suggests a potential role for fungal pulmonary infection in the pathogenesis of asthma. J. Infect. Dis. 193: 11781186.
47. Goldman,, D. L.,, H. Khine,, J. Abadi,, D. J. Lindenberg,, L. Pirofski,, R. Niang, and A. Casadevall. 2001. Serologic evidence for Cryptococcus infection in early childhood. Pediatrics 107: E66.
48. Gordon, M. A., and, A. Casadevall. 1995. Serum therapy of cryptococcal meningitis. Clin. Infect. Dis. 21: 14771479.
49. Goren, M. B. 1967. Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J. Immunol. 98: 914922.
50. Goren, M. B., and, G. M. Middlebrook. 1967. Protein conjugates of polysaccharide from Cryptococcus neoformans. J. Immunol. 98: 901913.
51. Guimaraes,, A. J.,, S. Frases,, F. J. Gomez,, R. M. Zancope-Oliveira, and, J. D. Nosanchuk. 2009. Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum. Infect. Immun. 77: 13571367.
52. Huang,, C.,, S. H. Nong,, M. K. Mansour,, C. A. Specht, and, S. M. Levitz. 2002. Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-cell responses. Infect. Immun. 70: 54855493.
53. Kakeya,, H.,, H. Udono,, N. Ikuno,, Y. Yamamoto,, K. Mitsutake,, T. Miyazaki,, K. Tomono,, H. Koga,, T. Tashiro,, E. Nakayama, and S. Kohno. 1997. A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect. Immun. 65: 16531658.
54. Kakeya,, H.,, H. Udono,, S. Maesaki,, E. Sasaki,, S. Kawamura,, M. A. Hossain,, Y. Yamamoto,, T. Sawai,, M. Fukuda,, K. Mitsutake,, Y. Miyazaki,, K. Tomono,, T. Tashiro,, E. Nakayama, and S. Kohno. 1999. Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. Clin. Exp. Immunol. 115: 485490.
55. Klein,, M.,, N. Shibli,, N. Friedmann,, G. B. Thornton,, R. Chisin, and M. Lotem. 2008. Imaging of metastatic melanoma (MM) with a 188Rhenium(188Re)-labeled melanin binding antibody. J. Nucl. Med. 49(Suppl 1): 52P.
56. Kozel, T. R., and, J. Cazin, Jr. 1972. Immune response to Cryptococcus neoformans soluble polysaccharide. Infect. Immun. 5: 3541.
57. Kozel, T. R.,, W. F. Gulley, and, J. J. Cazin. 1977. Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun. 18: 701707.
58. Lam,, J. S.,, M. K. Mansour,, C. A. Specht, and, S. M. Levitz. 2005. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J. Immunol. 175: 74967503.
59. Larsen,, R. A.,, P. G. Pappas,, J. R. Perfect,, J. A. Aberg,, A. Casadevall,, G. A. Cloud,, R. James,, S. Filler, and, W. E. Dismukes. 2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49: 952958.
60. Levitz,, S. M.,, S. Nong,, M. K. Mansour,, C. Huang, and, C. A. Specht. 2001. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA 98: 1042210427.
61. Levitz, S. M., and, E. A. North. 1997. Lymphopriliferation and cytokine profiles in human peripheral blood mononuclear cells stimulated by Cryptococcus neoformans. J. Med. Vet. Mycol. 35: 229236.
62. Littman, M. L. 1959. Cryptococcosis (torulosis). Current concepts and therapy. Am. J. Med. 27: 976998.
63. Lortholary,, O.,, A. Fontanet,, N. Memain,, A. Martin,, K. Sitbon, and F. Dromer. 2005. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 19: 10431049.
64. Maitta,, R.,, K. Datta,, Q. Chang,, R. Luo,, K. Subramanian,, B. Witover, and L. Pirofski. 2004. Protective and non-protective human IgM monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificity and gene usage. Infect. Immun. 22: 40624068.
65. Maitta, R.,, K. Datta,, A. Lees,, S. Belouski, and, L. Pirofski. 2003. Immunogenicity and efficacy of cryptococcal glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice. Infect. Immun. 72: 196208.
66. Mansour, M. K.,, E. Latz, and, S. M. Levitz. 2006. Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J. Immunol. 176: 30533061.
67. Mansour, M. K.,, L. S. Schlesinger, and, S. M. Levitz. 2002. Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J. Immunol. 168: 28722879.
68. Mansour,, M. K.,, L. E. Yauch,, J. B. Rottman, and, S. M. Levitz. 2004. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72: 17461754.
69. Martinez,, L. R.,, R. A. Bryan,, C. Apostolidis,, A. Morgenstern,, A. Casadevall, and E. Dadachova. 2006. Antibodyguided alpha radiation effectively damages fungal biofilms. Antimicrob. Agents Chemother. 50: 21322136.
70. Matthews, R.,, S. Hodgetts, and, J. Burnie. 1995. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J. Infect. Dis. 171: 16681771.
71. Matthews,, R. C.,, G. Rigg,, S. Hodgetts,, T. Carter,, C. Chapman,, C. Gregory,, C. Illidge, and J. Burnie. 2003. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47: 22082216.
72. May, R. J.,, D. O. Beenhouwer, and, M. D. Scharff. 2003. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development. J. Immunol. 171: 49054912.
73. McFadden, D. C., and, A. Casadevall. 2004. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans. J. Immunol. 172: 36703677.
74. McLean,, G. R.,, M. Torres,, N. Elguezabal,, A. Nakouzi, and A. Casadevall. 2002. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J. Immunol. 169: 13791386.
75. Moragues,, M. D.,, M. J. Omaetxebarria,, N. Elguezabal,, M. J. Sevilla,, S. Conti,, L. Polonelli, and J. Ponton. 2003. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti- C. albicans activities. Infect. Immun. 71: 52735279.
76. Mukherjee, J.,, M. Feldmesser,, M. D. Scharff, and, A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob. Agents Chemother. 39: 13981405.
77. Mukherjee, J.,, G. Nussbaum,, M. D. Scharff, and, A. Casadevall. 1995. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181: 405409.
78. Mukherjee, J.,, M. D. Scharff, and, A. Casadevall. 1992. Protective murine monoclonal anttibodies o Cryptococcus neoformans. Infect. Immun. 60: 45344541.
79. Mukherjee, J.,, L. Zuckier,, M. D. Scharff, and, A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob. Agents Chemother. 38: 580587.
80. Murphy, J. W. 1988. Influence of cryptococcal antigens on cell-mediated immunity. Rev. Infect. Dis. 10(Suppl. 2):S432–S435.
81. Murphy, J. W., and, G. C. Cozad. 1972. Immunological unresponsiveness induced by cryptococcal polysaccharide assayed by the hemolytic plaque technique. Infect. Immun. 5: 896901.
82. Murphy,, J. W.,, R. L. Mosley,, R. Cherniak,, G. H. Reyes,, T. R. Kozel, and E. Reiss. 1988. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect. Immun. 56: 424431.
83. Murphy, J. W.,, F. Shafer,, A. Casadevall, and, A. Adesina. 1998. Antigen-induced protective and non-protective cell-mediated immune components against Cryptococcus neoformans. Infect. Immun. 66: 26322639.
84. Nakouzi, A., and, A. Casadevall. 2003. The function of conserved amino acids at or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan. Mol. Immunol. 40: 351361.
85. Nakouzi,, A.,, P. Valadon,, J. D. Nosanchuk,, N. S. Green, and A. Casadevall. 2001. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans that elicit protective and non-protective antibodies. Infect. Immun. 69: 33983409.
86. Nakouzi, A.,, T. Zhang,, S. Oscarson, and, A. Casadevall. 2009. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies. Vaccine 27: 35133518.
87. Nooney, L.,, R. C. Matthews, and, J. P. Burnie. 2005. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51: 1929.
88. Orendi,, J. M.,, A. F. M. Verheul,, N. M. de Vos,, M. R. Visser,, H. Snippe,, R. Cherniak,, V. V. Vaishnav,, G. T. Rijkers, and J. Verhoef. 1997. Mannoproteins of Cryptococcus neoformans induce proliferative response in human peripheral blood mononuclear cells (PBMC) and enhance HIV replication. Clin. Exp. Immunol. 107: 293299.
89. Oscarson, S.,, M. Alpe,, P. Svahnberg,, A. Nakouzi, and, A. Casadevall. 2005. Synthesis and immunological studies of glycoconjugates of Cryptococcus neoforman s capsular glucuronoxylomannan oligosaccharide structures. Vaccine 23: 39613972.
90. Perfect, J. R., and, A. Casadevall. 2002. Cryptococcosis. Infect. Dis. Clin. North Am. 16: 837874., v–vi.
91. Pietrella,, D.,, R. Cherniak,, C. Strappini,, S. Perito,, P. Mosci,, F. Bistoni, and A. Vecchiarelli. 2001. Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans. Infect. Immun. 69: 28082814.
92. Pietrella,, D.,, R. Mazzolla,, P. Lupo,, L. Pitzurra,, M. J. Gomez,, R. Cherniak, and A. Vecchiarelli. 2002. Mannoprotein from Cryptococcus neoformans promotes T-helper type 1 anticandidal responses in mice. Infect. Immun. 70: 66216627.
93. Pirofski, L.,, R. Lui,, M. DeShaw,, A. B. Kressel, and, Z. Zhong. 1995. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63: 30053014.
94. Pitzurra, L.,, S. Perito,, F. Baldelli,, F. Bistoni, and, A. Vecchiarelli. 2003. Humoral response against Cryptococcus neoformans mannoprotein antigens in HIV-infected patients. Clin. Exp. Immunol. 133: 9196.
95. Pitzurra, L.,, A. Vecchiarelli,, R. Peducci,, A. Cardinali, and, F. Bistoni. 1997. Identification of a 105 kilodalton Cryptococcus neoformans mannoprotein involved in human cell-mediated immune response. J. Med. Vet. Mycol. 35: 299303.
96. Rachini,, A.,, D. Pietrella,, P. Lupo,, A. Torosantucci,, P. Chiani,, C. Bromuro,, C. Proietti,, F. Bistoni,, A. Cassone, and A. Vecchiarelli. 2007. An anti-{beta} glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anti-cryptococcal activity in vivo. Infect. Immun. 75: 50855094.
97. Rivera, J., and, A. Casadevall. 2005. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J. Immunol. 174: 80178026.
98. Robbins, J. B.,, R. Schneerson,, P. Anderson, and, D. H. Smith. 1996. The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 276: 11811185.
99. Rodrigues,, M. L.,, L. R. Travassos,, K. R. Miranda,, A. J. Franzen,, S. Rozental,, W. De Souza,, C. S. Alviano, and E. Barreto-Bergter. 2000. Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth. Infect. Immun. 68: 70497060.
100. Rosas, A. L.,, J. D. Nosanchuk, and, A. Casadevall. 2001. Passive immunization with melanin-binding monoclonal antibodies prolongs survival in mice with lethal Cryptococcus neoformans infection. Infect. Immun. 69: 34103412.
101. Rosas,, A. L.,, J. D. Nosanchuk,, M. Feldmesser,, G. M. Cox,, H. C. McDade, and A. Casadevall. 2000. Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect. Immun. 68: 28452853.
102. Sanford,, J. E.,, D. M. Lupan,, A. M. Schlagetter, and, T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58: 19191923.
103. Segal, E. 1987. Vaccines against fungal infections. CRC Crit. Rev. Microbiol. 14: 229273.
104. Singh,, N.,, O. Lortholary,, B. D. Alexander,, K. L. Gupta,, G. T. John,, K. Pursell,, P. Munoz,, G. B. Klintmalm,, V. Stosor,, R. del Busto,, A. P. Limaye,, J. Somani,, M. Lyon,, S. Houston,, A. A. House,, T. L. Pruett,, S. Orloff,, A. Humar,, L. Dowdy,, J. Garcia-Diaz,, A. C. Kalil,, R. A. Fisher, and S. Husain. 2005. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40: 17561761.
105. Subramaniam,, K.,, B. Metzger,, L. H. Hanau,, A. Guh,, L. Rucker,, S. Badri, and, L. A. Pirofski. 2009. IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. J. Infect. Dis. 200: 244251.
106. Subramaniam, K. S.,, N. French, and, L. Pirofski. 2005. Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans. Clin. Diagn. Lab Immunol. 12: 11681176.
107. Taborda, C. P., and, A. Casadevall. 2001. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence and prozone-like effects in passive protection experiments. J. Immunol. 66: 21002107.
108. Taborda, C. P.,, J. Rivera,, O. Zaragoza, and, A. Casadevall. 2003. More is not necessarily better: “Prozone-like” effects in passive immunization with immunoglobulin G. J. Immunol. 140: 36213630.
109. Torosantucci,, A.,, C. Bromuro,, P. Chiani,, F. De Bernardis,, F. Berti,, C. Galli,, F. Norelli,, C. Bellucci,, L. Polonelli,, P. Costantino,, R. Rappuoli, and A. Cassone. 2005. A novel glycoconjugate vaccine against fungal pathogens. J. Exp. Med. 202: 597606.
110. Torosantucci,, A.,, P. Chiani,, C. Bromuro,, F. De Bernardis,, A. S. Palma,, Y. Liu,, G. Mignogna,, B. Maras,, M. Colone,, A. Stringaro,, S. Zamboni,, T. Feizi, and A. Cassone. 2009. Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4: E5392.
111. Valadon,, P.,, G. Nussbaum,, L. F. Boyd,, D. H. Margulies, and, M. D. Scharff. 1996. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol. 261: 1122.
112. Vecchiarelli, A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38: 407417.
113. Vecchiarelli, A. 2007. Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity. Crit Rev. Immunol. 27: 547557.
114. Vesely, J.,, L. Rydner, and, S. Oscarson. 2008. Variant synthetic pathway to glucuronic acid-containing di- and trisaccharide thioglycoside building blocks for continued synthesis of Cryptococcus neoformans capsular polysaccharide structures. Carbohydr. Res. 343: 22002208.
115. Walzl,, G.,, I. R. Humphreys,, B. G. Marshall,, L. Edwards,, P. J. Openshaw,, R. J. Shaw, and T. Hussell. 2003. Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner. Infect. Immun. 71: 33843391.
116. Wang,, X. G.,, E. Revskaya,, R. A. Bryan,, H. D. Strickler,, R. D. Burk,, A. Casadevall, and E. Dadachova. 2007. Treating cancer as an infectious disease: viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS ONE 2: E1114.
117. Williams,, A. E.,, L. Edwards,, I. R. Humphreys,, R. Snelgrove,, A. Rae,, R. Rappuoli, and T. Hussell. 2004. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J. Immunol. 173: 74357443.
118. Wormley, F. L., Jr.,, G. M. Cox, and, J. R. Perfect. 2005. Evaluation of host immune responses to pulmonary cryptococcosis using a temperature-sensitive C. neoformans calcineurin A mutant strain. Microb. Pathog. 38: 113123.
119. Wormley,, F. L.,, Jr.,, J. R. Perfect,, C. Steele, and, G. M. Cox. 2007. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect. Immun. 75: 14531462.
120. Wozniak, K. L., and, S. M. Levitz. 2009. Isolation and purification of antigenic components of Cryptococcus. Methods Mol. Biol. 470: 7183.
121. Yuan, R.,, A. Casadevall,, J. Oh, and, M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94: 24832488.
122. Zebedee,, S. L.,, R. K. Koduri,, J. Mukherjee,, S. Mukherjee,, S. Lee,, D. F. Sauer,, M. D. Scharff, and A. Casadevall. 1994. Mouse-human immunoglobulin G1 chimeric antibodies with activity against Cryptococcus neoformans. Antimicrob. Agents Chemother. 38: 15071514.
123. Zhang, H.,, Z. Zhong, and, L. Pirofski. 1997. Peptide epitopes recognized by a human anticryptococcal glucuronoxylomannan antibody. Infect. Immun. 65: 11581164.
124. Zhang, J., and, F. Kong. 2003. Facile syntheses of the hexasaccharide repeating unit of the exopolysaccharide from Cryptococcus neoformans serovar A. Bioorg. Med. Chem. 11: 40274037.
125. Zhang, J., and, F. Kong. 2003. Synthesis of a hexasaccharide, the repeating unit of O-deacetylated GXM of C. neoformans serotype A. Carbohydr. Res. 338: 17191725.
126. Zhong, Z., and, L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect. Immun. 64: 34463450.
127. Zhong, Z., and, L. Pirofski. 1998. Antifungal activity of a human anti-glucuronoxylomannan antibody. Clin. Diagn. Lab. Immunol. 5: 5864.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error